POMDOCTOR LIMITED has changed its independent registered public accounting firm. On April 20, 2026, the company dismissed Marcum Asia CPAs LLP and appointed HYYH CPA LLC to audit its consolidated financial statements for the year ended December 31, 2025.
The company states there were no disagreements with Marcum on accounting principles, financial statement disclosure, or audit scope for the years ended December 31, 2023 and 2024, and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting. These weaknesses include insufficient U.S. GAAP/SEC expertise, incomplete financial reporting policies and procedures, and weaknesses in system access security and change management.
POMDOCTOR Ltd director Li Daxue Donnelly has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The excerpt shows no reported transactions or derivative positions, indicating this filing is primarily an administrative disclosure of insider status rather than trading activity.
POMDOCTOR LIMITED reported that Dexiang Wei resigned as Vice President, with the resignation dated March 31, 2026 and effective April 1, 2026. The company states that his departure was not due to any disagreement with the Board on operations, policies, or practices, and there are no related matters requiring shareholder attention.
POMDOCTOR Ltd director Jing Yuanyuan Crystal filed an initial Form 3, which is a mandatory disclosure of insider status. The filing shows no reported transactions or share holdings at this time, serving only to register her as a reporting insider of the company.
POMDOCTOR Ltd filed an initial ownership report showing that Chief Financial Officer Xu Li jinfuhua has an indirect interest in 800,000 Class B ordinary shares held by HEALTHYTEN LIMITED. These Class B shares carry twenty votes per share, compared with one vote for each Class A ordinary share.
Each Class B ordinary share is convertible into one Class A ordinary share at any time by its holder, while Class A ordinary shares are not convertible into Class B ordinary shares. HEALTHYTEN LIMITED is wholly owned by Li Xu, who has granted an irrevocable voting proxy over all Class B shares beneficially owned by HEALTHYTEN LIMITED to Zhenyang Shi.
POMDOCTOR Ltd officer Wei Dexiang filed an initial Form 3 as a reporting person for the company’s securities. Wei is identified as a Vice President, and this filing establishes their insider status and disclosure obligations. No share transactions or holdings are reported in this Form 3 submission.
POMDOCTOR Ltd filed an initial insider ownership report for Luo Guoji. The filing identifies Luo as both a director and an officer of the company, serving as Vice President. It does not list any transactions in POMDOCTOR Ltd securities in connection with this filing.
POMDOCTOR Ltd director and CEO Shi Zhenyang has filed an initial Form 3 disclosing indirect ownership of the company’s dual-class shares. The filing reports indirect holdings of Class A ordinary shares through entities including HEALTHYSEVEN LIMITED and several Guangzhou management consulting partnerships, and Class B ordinary shares through HEALTHYSEVEN LIMITED and HEALTHYTEN LIMITED.
The company’s capital structure includes Class A and Class B ordinary shares. Each Class B share carries twenty votes, while each Class A share carries one vote, and each Class B share is convertible into one Class A share at the holder’s option.
POMDOCTOR LIMITED is launching a strategic initiative to deepen integration between its online chronic-disease platform and China’s national and local medical insurance systems across major cities. This aims to broaden market reach and make reimbursed online care more convenient for patients, internet hospitals, and pharmacies.
The company already supports online insurance settlements for chronic and special disease outpatients in Guangzhou and plans expansion to other Greater Bay Area cities, including Foshan in the first quarter of 2026, as well as Beijing, Shanghai, Tianjin, Chengdu, Xi’an, Nanjing, Hangzhou, and Fuzhou. Patients can complete consultations, receive digital prescriptions, obtain near-real-time insurance reimbursement, and have medications delivered to their homes, reflecting China’s shift toward standardized, large-scale internet healthcare.
POMDOCTOR LIMITED reported that Nasdaq has notified the company its American depositary shares have failed to meet the minimum bid price requirement of US$1.00 for 33 consecutive business days. This triggers a compliance period but does not immediately affect listing or trading of the ADSs.
Under Nasdaq rules, Pomdoctor has 180 calendar days, until July 28, 2026, to regain compliance. If the ADS closing bid price is at least US$1.00 for a minimum of ten consecutive business days during this period, Nasdaq will confirm compliance and close the matter. The company states that the notice has no effect on its business operations and that it will take reasonable measures to regain compliance.